Retreatment with higher-dose upadacitinib for ulcerative colitis flare
Treatments studied
Part of Digestive system clinical trials.
This study tests whether a higher dose of upadacitinib (45 mg) can help people with ulcerative colitis whose symptoms come back while on the usual 30 mg maintenance dose. If you've lost response to your current treatment, this re-induction approach may help you get back into remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 64 years old.
- You have ulcerative colitis that is moderate to severe and you've been taking upadacitinib 30 mg daily.
- You initially noticed improvement with upadacitinib, but your symptoms have recently returned or worsened.
- Your blood tests show certain levels that are safe for this study (doctor will check).
- You have not had your colon removed or had an ileostomy or pouch surgery.
- You are willing to follow the study procedures and use birth control if applicable.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
Researchers want to see if taking two medications together (upadacitinib and vedolizumab) works better than taking just upadacitinib alone for people with moderate to severe ulcerative colitis. This is a real-world study, meaning it looks at patients being treated in normal medical practice.
This trial tests whether two medications, vedolizumab (a biologic given by IV) and upadacitinib (a pill), work together to help people with moderate to severe ulcerative colitis. The goal is to see if this combination is safe and effective for controlling symptoms and healing the colon.
This study tests whether upadacitinib, a pill that calms the immune system, can help people hospitalized with a severe flare of ulcerative colitis. It aims to see if the drug can reduce symptoms and help you leave the hospital sooner.
This trial tests two different medicines, infliximab and upadacitinib, to see which works better for people with severe ulcerative colitis that hasn't improved after 3 days of IV steroids. The goal is to find the best rescue option to help you feel better and avoid surgery.
This study tests a medication called upadacitinib for people with inflammatory bowel disease (ulcerative colitis or Crohn's). The goal is to see how well it works and if it's safe.
This study compares two medications—upadacitinib and infliximab—as second-line treatments for acute severe ulcerative colitis (a serious flare of inflammatory bowel disease). The trial will help doctors understand which treatment works better when standard first-line therapy hasn't controlled the inflammation.
Hear when a new Ulcerative Colitis (UC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.